Retagliptin Phosphate Tablets approved by China NMPA for type 2 diabetes

Jun,2023. Retagliptin Phosphate Tablets, the Class 1. New drug from Jiangsu Hengrui Pharmaceuticals Co., Ltd for the treatment of type 2 diabetes, is approved by China NMPA.

Retagliptin phosphate is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor that inhibits DPP-4 to hydrolyze the incretin hormone, thereby increasing the plasma concentration of active glucagon-like peptide-1 (GLP-1) and glucose dependent insulin-like polypeptide (GIP). It increases the release of insulin in a glucose dependent manner and decreases glucagon to reduce blood glucose.

Phase III clinical trail result shows that Retagliptin Phosphate Tablets can significantly reduce HbA1c levels by 1.13% and decrease postprandial blood sugar by 2.69mmol/L in patients with type 2 diabetes. The combination of 50mg BID of Retagliptin Phosphate Tablets and metformin can further reduce HbA1c levels by 1.18% and decrease postprandial blood sugar by 2.71mmol/L in patients with type 2 diabetes. The results indicate that Rigelitinib has a stable therapeutic effect and provides stable blood sugar management for diabetic patients.

As DPP-4 inhibitors,Retagliptin Phosphate Tablets have a unique mechanism of reducing blood sugar levels that can be combined with other anti-diabetic medications to achieve a synergistic effect in lowering blood sugar. When used in combination, DPP-4 inhibitors do not increase the risk of hypoglycemia or gastrointestinal adverse reactions. Additionally, Retagliptin Phosphate Tablets has no induction effect on CYP450 enzymes, and the risk of drug-drug interaction is low, which will promote personalized combination therapy for diabetic patients.